Syapse and Roche have entered into a multi-year strategic collaboration to help make precision medicine available to more cancer patients.
 
Syapse and Roche will work jointly to develop software products and analytics solutions to provide the tools and insights healthcare providers need to practice precision medicine at scale, with the goal of improving patient outcomes.
 
Roche will fund the development of these products, which aim to benefit oncologists, health systems, and stakeholders including payers. Syapse will develop and deploy these new products to the precision medicine ecosystem, beginning with its existing healthcare provider network.
 
The companies will initially focus on four product programs: real-world evidence, so that physicians can make better care decisions; better understanding the health economics impact and patient outcomes of precision medicine; advancing electronic patient-reported outcomes to understand precision medicine’s effect on health-related quality of life; and accelerating clinical trial enrollment by matching patients to precision trials at the point of care.

Roche and Syapse will also collaborate on automated methods for measuring real-world outcomes.

“Precision medicine is already improving cancer care, and Syapse is empowering healthcare providers with the tools they need to deliver the best possible care,” said Ken Tarkoff, chief executive officer of Syapse. “By working together, Syapse and Roche can make this vision of precision medicine a reality faster than either of us could alone.”

“Roche and Syapse share a common vision of ensuring widespread access to precision medicine so we can dramatically improve patient care,” said Daniel O’Day, chief executive officer of Roche Pharmaceuticals. “This collaboration supports that vision. By combining the pioneering platform from Syapse and Roche’s expertise in oncology, we can bring personalized healthcare to many more patients and healthcare providers.”